slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 5,641-5,670
Pages 296
Rows per page 30
Slide type
5,641-5,670 of 8,880
32
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
34
Enochian Biosciences | Results Presentation Deck | 43 slidesEnochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a comparative diagram to illustrate the selective mechanism of action.Enochian Biosciences | Results Presentation Deck | 43 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
13
The slide illustrates a structural biology approach to drug design, focusing on helix-receptor interactions and sequence engineering.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
14
The slide uses a combination of biological process diagrams and a bar chart to demonstrate selective inhibition.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
18
The slide uses a four-column structure to explain the target, the molecule type, preclinical results, and clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cell activation and hair follicle damage.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses a four-column structure to explain the biological rationale, molecular nature, mechanism of action, and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to show the mechanism of action and a bar chart to show efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
26
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
48
The slide uses western blot data to demonstrate the efficacy of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
09
The slide uses a split-screen layout contrasting technical search methodology with user-centric quality goals.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations Beat · Solution1 hit
06
The central figure represents the patient, with six surrounding nodes representing different technological capabilities.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations Beat · Solution1 hit
14
The slide uses a complex diagram combining a linear process flow with a double-loop feedback mechanism (flywheel).Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
15
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
19
The slide uses a circular flow diagram to represent the integration of experimental and AI-driven precision medicine.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
20
The slide highlights the integration of various data sources (Knowledge Graphs, Neural Networks, Literature/Patent Databases, Multi-omics, Vector Embedding) into a unified AI workflow.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
22
The slide illustrates a drug discovery workflow using MPO (Multiparameter Optimisation) to balance multiple biological and chemical constraints.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
23
The diagram illustrates a multi-modal AI pipeline for drug discovery.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
25
The chart illustrates a Pareto frontier where the AI selects compounds that are not necessarily the highest in potency but provide high information gain.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit